Esperion Therapeutics Gets Positive Results For LDL Lowering Drug
PLYMOUTH - Esperion Therapeutics announced positive results from a Phase 2 clinical trial for ETC-1002, an LDL cholesterol lowering drug. This small molecule activator of AMP Kinase has demonstrated preclinical and clinical activity as a metabolic regulator of imbalances in lipid and carbohydrate metabolism. Results were presented Tuesday in an oral presentation at the 2012